Given a patient with an eGFR of 42 mL/min/1.73 m², serum uric acid of 19 mg/dL, creatinine of 1.66 mg/dL, and current medications allopurinol 300 mg daily, hydrochlorothiazide 25 mg daily, losartan 25 mg daily, metformin 500 mg daily, and tirzepatide (Mounjaro) 10 mg subcutaneously weekly, how should the medication regimen be adjusted?

Immediate Medication Adjustments Required

This patient requires urgent discontinuation of hydrochlorothiazide and dose reduction of metformin, with consideration for switching from allopurinol to febuxostat given the severely elevated uric acid and moderate CKD. The current regimen contains multiple medications that are either contraindicated, inappropriately dosed, or contributing to the hyperuricemia crisis.

Critical Issues Identified

1. Hydrochlorothiazide 25 mg Daily - DISCONTINUE IMMEDIATELY

Stop this medication now 1. Thiazide diuretics are directly contraindicated in gout management and are likely contributing significantly to the severely elevated uric acid of 19 mg/dL. The EULAR guidelines explicitly state: "When gout occurs in a patient receiving loop or thiazide diuretics, substitute the diuretic if possible; for hypertension consider losartan or calcium channel blockers" 1.

• The patient is already on losartan 25 mg, which has mild uricosuric properties and is the preferred antihypertensive in gout
• Action: Discontinue hydrochlorothiazide and increase losartan dose (can titrate up to 100 mg daily for blood pressure control if needed) 1
• Alternative: Add a calcium channel blocker if additional blood pressure control is required 2

2. Metformin 500 mg Daily - REDUCE DOSE

Reduce metformin to 500 mg daily (already at appropriate dose) but monitor closely 3, 4. With eGFR 42 mL/min/1.73 m², this patient is in the 30-44 range where:

• Maximum recommended dose is 1000 mg daily 3, 4
• Current dose of 500 mg is acceptable but represents the lower end of therapeutic dosing
• Critical: Monitor eGFR every 3-6 months; discontinue if eGFR drops below 30 3, 5
• Consider dose reduction to 500 mg every other day or discontinuation if patient develops acute illness, dehydration, or contrast exposure 3

3. Allopurinol 300 mg Daily - INADEQUATE AND POTENTIALLY INAPPROPRIATE

The current allopurinol regimen is failing catastrophically (uric acid 19 mg/dL vs target <6 mg/dL) 1. With eGFR 42, the patient is in CKD stage 3b, where:

Option A (Preferred): Switch to Febuxostat

• Febuxostat does not require dose adjustment in renal impairment 1
• Start febuxostat 40 mg daily, can increase to 80 mg daily after 2-4 weeks if uric acid remains >6 mg/dL
• This is explicitly recommended when "the SUA target cannot be achieved at appropriate allopurinol dose" in renal impairment 1

Option B: Optimize Allopurinol Dosing (Less Preferred)

• EULAR guidelines state: "In patients with renal impairment, the allopurinol maximum dosage should be adjusted to creatinine clearance" 1
• For eGFR 30-44, traditional teaching suggests max 200 mg daily, though recent evidence suggests higher doses may be safe 6
• However, with uric acid at 19 mg/dL, allopurinol is clearly inadequate regardless of dose adjustment
• If continuing allopurinol, could cautiously increase to 200 mg daily with close monitoring, but febuxostat switch is superior

4. Tirzepatide (Mounjaro) 10 mg Weekly - CONTINUE

Continue tirzepatide without dose adjustment 7. The medication is:

• Approved for use in CKD with no dose adjustment required 8
• May actually improve kidney function through weight loss and metabolic effects 9
• Monitor for volume depletion and gastrointestinal side effects that could worsen kidney function 7
• Ensure adequate hydration given risk of volume depletion with GLP-1 agonists in CKD 7

5. Losartan 25 mg Daily - CONTINUE AND CONSIDER INCREASE

Continue losartan and consider dose escalation 2, 4:

• Current dose is subtherapeutic for both hypertension and renoprotection
• Can increase to 50-100 mg daily for better blood pressure control after stopping hydrochlorothiazide
• Losartan has mild uricosuric effects, making it the preferred ARB in gout 1
• Monitor potassium closely, especially if increasing dose

Severe Hyperuricemia Management (Uric Acid 19 mg/dL)

This represents a medical urgency requiring aggressive intervention:

Immediate Actions:

1. Assess for acute gout flare or tumor lysis syndrome - uric acid of 19 mg/dL is dangerously elevated
2. Check for acute kidney injury - this level of hyperuricemia can cause uric acid nephropathy
3. Hydration: Ensure adequate fluid intake (2-3 L/day if tolerated) to prevent uric acid crystallization 10
4. Discontinue hydrochlorothiazide immediately - likely major contributor 1

Target Uric Acid Goals:

• Initial target: <6 mg/dL (360 μmol/L) 1
• Given severity, may need target <5 mg/dL initially for faster crystal dissolution 1
• Long-term maintenance: <6 mg/dL 1

Gout Flare Prophylaxis:

Start colchicine prophylaxis when initiating/changing urate-lowering therapy 1:

• Dose with eGFR 30-44: Colchicine 0.3 mg daily (reduced from standard 0.5-1 mg due to renal impairment) 1
• Continue for 6 months after starting febuxostat or adjusting allopurinol
• Critical warning: Risk of neurotoxicity/myotoxicity in renal impairment, especially with statins if patient is on one 1
• Monitor closely for muscle pain, weakness, or neuropathy

Summary of Medication Changes

Medication	Current Dose	Recommended Action	New Dose	Rationale
Hydrochlorothiazide	25 mg daily	STOP	Discontinue	Contraindicated in gout, worsening hyperuricemia [1]
Metformin	500 mg daily	Continue, monitor closely	500 mg daily	Appropriate for eGFR 30-44; max 1000 mg [3,4]
Allopurinol	300 mg daily	SWITCH to febuxostat	Febuxostat 40 mg daily	Failing to control uric acid; febuxostat preferred in CKD [1]
Losartan	25 mg daily	Increase	50-100 mg daily	Subtherapeutic; preferred in gout [1,2]
Tirzepatide	10 mg weekly	Continue	10 mg weekly	No adjustment needed; may improve kidney function [7,9]
Colchicine	None	ADD	0.3 mg daily × 6 months	Flare prophylaxis during ULT adjustment [1]

Monitoring Plan

Week 1-2:

• Recheck uric acid, creatinine, eGFR
• Assess blood pressure after stopping hydrochlorothiazide
• Monitor for gout flare (should be covered by colchicine)

Month 1:

• Uric acid, creatinine, eGFR, potassium
• If uric acid still >6 mg/dL on febuxostat 40 mg, increase to 80 mg daily
• Assess blood pressure control; adjust losartan if needed

Month 3:

• Uric acid (target <6 mg/dL achieved)
• eGFR, creatinine
• Consider discontinuing colchicine if no flares and uric acid at goal

Ongoing:

• eGFR every 3-6 months (critical for metformin safety) 3
• Uric acid every 3-6 months once at goal
• Annual vitamin B12 if continuing metformin long-term 3

Common Pitfalls to Avoid

1. Do not continue hydrochlorothiazide - this is actively harmful in gout and likely the primary driver of the uric acid elevation to 19 mg/dL
2. Do not increase metformin dose - already at maximum safe dose for this eGFR
3. Do not stop allopurinol abruptly without bridging - can precipitate acute gout flare; overlap with colchicine prophylaxis
4. Do not underdose colchicine prophylaxis - but also do not use standard doses in CKD (risk of toxicity)
5. Do not forget to recheck kidney function - metformin becomes contraindicated if eGFR drops below 30

The combination of stopping the thiazide diuretic and switching to febuxostat should dramatically improve the hyperuricemia while the current tirzepatide and appropriately-dosed metformin continue to provide glycemic control and potential renoprotection.